scholarly journals Suppressed expression of blood group B antigen and blood group galactosyltransferase in a preleukemic subject

Blood ◽  
1985 ◽  
Vol 66 (4) ◽  
pp. 990-992 ◽  
Author(s):  
A Yoshida ◽  
T Kumazaki ◽  
V Dave ◽  
J Blank ◽  
WH Dzik
Keyword(s):  
Bone Marrow ◽  
Blood Group ◽  
Viral Oncogene ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Antigen Activity ◽  
Preleukemic Stage

Abstract The B antigen activity was severely diminished in a patient's RBCs at the preleukemic stage prior to chemo- or radiotherapy. The amount of H sites of the patient's RBC membranes was found to be comparable to that of O RBC membranes. The activity of alpha (1----2) fucosyltransferase (H enzyme) was not severely decreased in the patient's plasma and bone marrow. However, the activity of alpha (1----3) galactosyltransferase (B enzyme), which converts H substance to B substance, was drastically reduced in the patient's bone marrow. Thus, the diminished B antigen in the patient's RBCs was caused mainly by the blockage of conversion of the H substance to B substance. It is suggested that the viral oncogene linked to the ABO locus at q34 of chromosome No. 9 would occasionally suppress the expression of blood group A and B enzymes and A and B antigens.

scholarly journals Suppressed expression of blood group B antigen and blood group galactosyltransferase in a preleukemic subject

Blood ◽  
1985 ◽  
Vol 66 (4) ◽  
pp. 990-992
Author(s):  
A Yoshida ◽  
T Kumazaki ◽  
V Dave ◽  
J Blank ◽  
WH Dzik
Keyword(s):  
Bone Marrow ◽  
Blood Group ◽  
Viral Oncogene ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Antigen Activity ◽  
Preleukemic Stage

The B antigen activity was severely diminished in a patient's RBCs at the preleukemic stage prior to chemo- or radiotherapy. The amount of H sites of the patient's RBC membranes was found to be comparable to that of O RBC membranes. The activity of alpha (1----2) fucosyltransferase (H enzyme) was not severely decreased in the patient's plasma and bone marrow. However, the activity of alpha (1----3) galactosyltransferase (B enzyme), which converts H substance to B substance, was drastically reduced in the patient's bone marrow. Thus, the diminished B antigen in the patient's RBCs was caused mainly by the blockage of conversion of the H substance to B substance. It is suggested that the viral oncogene linked to the ABO locus at q34 of chromosome No. 9 would occasionally suppress the expression of blood group A and B enzymes and A and B antigens.

scholarly journals ABO groups can play a role in susceptibility and severity of COVID-19

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
S. Samra ◽  
M. Habeb ◽  
R. Nafae
Keyword(s):  
Blood Group ◽  
Abo Blood Group ◽  
Infection Group ◽  
Mechanically Ventilated ◽  
Blood Group A ◽  
Group A ◽  
Study Population ◽  
Group B ◽  
The Relationship ◽  
Seriously Ill

Abstract Background A few people infected by the coronavirus become seriously ill, while others show little to no signs of the symptoms, or are asymptomatic. Recent researches are pointing to the fact that the ABO blood group might play an important role in a person’s susceptibility and severity of COVID-19 infection. Aim of the study: try to understand the relationship between ABO groups and COVID-19 (susceptibility and severity). Results A total of (507) patients were included in this study. The study population was divided based on the ABO blood group into types A+, A−, B+, AB, O+, and O−. Blood group A was associated with high susceptibility of infection: group A, 381 (75.1%); and less common in group O, 97 (19.2%), group B, 18 (3.5%), and group AB, 11 (2.2%). The severity of COVID-19 infection was common in non-blood group O where (20 (7.1%), 4 (26.7%), 2 (11%), and 1 (9%) in type A+, A−, B+, and AB, respectively), while in type O 3.1%. And mechanically ventilated patients were 22 (5.9%), 2 (13.4%), 2 (11.1%), and 1 (1%). Mortality was high in blood groups A and B, 16 (4.37%) and 1 (5.5%), respectively, while in blood group O, it was 1%. Conclusion The incidence, severity, and mortality of COVID-19 were common in non-blood group O. While blood group O was protected against COVID-19.

scholarly journals Distribution of ABO and Rh blood groups in Nepalese medical students: a report

2000 ◽  
Vol 6 (1) ◽  
pp. 156-158
Author(s):  
T. Pramanik ◽  
S. Pramanik
Keyword(s):  
Medical Students ◽  
Blood Group ◽  
Blood Groups ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Group Distribution

The frequencies of ABO and rhesus blood groups vary from one population to another. We studied blood group distribution in 120 Nepalese students; 34% were blood group A, 29% group B, 4% group AB and 32.5% group O. The frequency of Rh-negative blood was 3.33% and Rh-positive 96.66%

scholarly journals The association between blood groups and maxillofacial deformities

2008 ◽  
Vol 41 (02) ◽  
pp. 138-140
Author(s):  
Rasoul Gheisari ◽  
Mehdi Ghoreishian ◽  
Movahedian Bijan ◽  
Roozbehi Amrolah
Keyword(s):  
Blood Group ◽  
Blood Groups ◽  
Iranian Population ◽  
The Other ◽  
Chi Square ◽  
Genetic Characteristics ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Group Distribution

ABSTRACT Background: Blood group is a genetic characteristic which is associated with some diseases and deformities. Multifactorial characteristics of facial development make it difficult to predict a genetic pattern in a specific maxillofacial deformity, but epidemiological evaluations can reveal relationships between such deformities and some genetic characteristics or accompanied diseases, and this will help to recognise and treat them. The aim of this study is evaluation of the relationship between blood groups and maxillofacial deformities. Materials and Methods: In this study, blood groups of 190 patients with maxillofacial deformities who had had orthognathic surgery in Alzahra hospital, Isfahan, were compared with the general Iranian population. Results: Among 190 patients, 93 cases (49%) were men and 97 cases (51%) were women. Fifteen cases (8%) were < 20 years old, 130 cases (68%) were 20-30 years old, and the others (45 cases, 24%) were > 30 years old. The blood group distribution in our samples was as follows: blood group O = 76 cases (40%), blood group A = 58 cases (30%), blood group B = 41 cases (22%), and blood group AB = 15 cases (8%). Among these patients, 31 cases (16%) had maxillary deformities and 27 cases (14%) suffered from mandibular deformities while the other 132 cases (70%) had bimaxillary problems. The Chi-square test showed statistically significant differences between the blood group distribution of the patients of this study and the normal Iranian population ( P < 0.001). Conclusion: It was shown that among different blood groups; those with blood group B have a greater likelihood of association with maxillofacial deformities. On the other hand, the probability of the association of such deformities was the least with blood group A.

scholarly journals Survival of Group A Erythrocytes Following Bone Marrow Transplantation for Reconstitution of Lymphopenic Hypogammaglobulinemia

Blood ◽  
1971 ◽  
Vol 38 (1) ◽  
pp. 60-65 ◽  
Author(s):  
M. M. AZAR ◽  
R. A. GATTI ◽  
E. J. YUNIS ◽  
J. SWANSON ◽  
R. A. GOOD
Keyword(s):  
Bone Marrow ◽  
Immune System ◽  
Bone Marrow Transplantation ◽  
Blood Group ◽  
Marrow Transplantation ◽  
Bone Marrow Transplants ◽  
Blood Group A ◽  
Group A ◽  
Immunological Destruction

Abstract The survival of chromium-labeled group A erythrocytes was measured in a patient who had previously received two bone marrow transplants for reconstitution of lymphopenic hypogammaglobulinemia. The patient was of blood group A before transplantation; the donor of blood group O. The patient’s erythrocytes are now virtually 100% group O. Anti-B titers are present; anti-A antibodies are not demonstrable. The cells producing these isohemagglutinins are of donor origin; the donor has anti-A titers of 1:64 in saline and 1:256 by antihuman globulin test as well as anti-B titers. No evidence of immunological destruction of group A erythrocytes was found in this patient suggesting that the immune system of the donor may have become tolerant of the group A substance of the recipient.

Prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for estimation of efficiency of therapy with the use of pegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C

2016 ◽  
Vol 94 (3) ◽  
pp. 224-230
Author(s):  
P. P. Ogurtsov ◽  
Elena I. Kukhareva
Keyword(s):  
Hepatitis C ◽  
Gene Polymorphism ◽  
Blood Group ◽  
Hepatic Fibrosis ◽  
Pegylated Interferon ◽  
Interleukin 28B ◽  
Blood Group A ◽  
Group Specificity ◽  
Group A ◽  
Group B

Aim. To estimate the prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for the achievement of sustained virologic response (SVR) to antiviral therapy (AVT) with the use ofpegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C (CHC-1). The secondary aim was to evaluate the influence of these genetic factors on the progress of hepatic fibrosis in case offailure of the above treatment. Materials and methods. A total of 146patients with CHC-1 were examined. We studied the RNA genotype of hepatitis C virus, blood group specificity, IL-28B gene polymorphism, and severity of hepatic fibrosis (puncture biopsies). Dynamics of hepatic fibrosis was followed up in 40 patients who failed to develop the virologic response. 20 control patients did not receive AVT. The multifactor significance criterion was used to identify the initial factor that produced the highest effect on SVR. Results. SVR was observed in 56.8% of the patients. Its efficiency was most significantly influenced by the combination of blood group specificity and interleukin 28B gene polymorphism (p=0.000024). Combination of blood group (0)1 with C/C or T/TIL-28B genotypes, A(II) with C/T or T/T, and B(III) with T/G was associated with SVR in 100, 88.2, and 94.4% cases respectively. It was absent in patients with blood group A(II) in combination with double-nucleotide substitution in rs8099917 of the IL-28B gene (TG and GG genotypes); these patients suffered progressive fibrosis. SVR occurred in 83.8% of the patients with blood group B(III). Conclusion. The knowledge of blood group in patients with CHC-1 and IL-28B gene polymorphism treated with the use of pegylated interferon a-2 and ribavarin allows to predict SVR with a probability of 100% in case of blood group 0(1) and C/C or T/T genotypes, 88.2% in case of blood group A(II) and single-nucleotide C>T substitution in rs8099917 locus of the IL-28B gene, 94.4% in case of blood group B(II) and single-nucleotide T>G substitution in the rs8099917 locus, 83.8% in case of blood group B(III). Treatment ofpatients with these genetic traits with antiviral drugs of direct action has no appreciable advances over treatment with AVT in combination with pegylated interferon a-2 and ribavarin (SVR above or around 85%). Patients with blood group A(II) and single- or double-nucleotide substitution in rs8099917 (TG or GG genotypes) have minimal chances to produce SVR to the above treatment. Simultaneous progression of hepatic fibrosis suggest that such therapy is undesirable in these cases. They should be regarded as main candidates for interferon-free therapy. Combination of blood group specificity and interleukin 28B gene polymorphism is a simple and reliable predictor of SVR and dynamics offibrosis in patients with CHC-1 receiving AVT with pegylated interferon a-2 and ribavirin; also, it may be an instrument of selection of patients for interferon-free therapy.

Antibody to histo-blood group A antigen neutralizes HIV produced by lymphocytes from blood group A donors but not from blood group B or O donors

AIDS ◽  
1991 ◽  
Vol 5 (4) ◽  
pp. 441-444 ◽  
Author(s):  
Maiken Arendrup ◽  
John-Erik Stig Hansen ◽  
Henrik Clausen ◽  
Claus Nielsen ◽  
Lars Reinhardt Mathiesen ◽  
...  
Keyword(s):  
Blood Group ◽  
Blood Group A ◽  
Group A ◽  
Group B
Sign in / Sign up

Export Citation Format

Share Document